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Abstract
Whole genome analysis approaches are revealing recurrent cancer-associated somatic alterations 
in non-coding DNA regions. We combined somatic copy number analysis of 12 tumor types with 
tissue-specific epigenetic profiling to identify significant regions of focal amplification harboring 
super-enhancers. Copy-number gains of non-coding regions harboring super-enhancers near 
KLF5, USP12, PARD6B and MYC are associated with over-expression of these cancer-related 
genes. We show that two distinct focal amplifications of super-enhancers 3′ to MYC in lung 
adenocarcinoma (MYC-LASE) and endometrial carcinoma (MYC-ECSE), are physically 
associated with the MYC promoter and correlate with MYC over-expression. CRISPR/Cas9-
mediated repression or deletion of a constituent enhancer within the MYC-LASE region led to 
significant reductions in the expression of MYC and its target genes, and to the impairment of 
anchorage-independent and clonogenic growth, consistent with an oncogenic function. Our results 
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demonstrate that genomic amplification of super-enhancers represents a common mechanism to 
activate cancer driver genes in multiple cancer types.
Somatic copy number alterations (SCNAs), including chromosome arm-level copy changes 
as well as focal amplifications and deletions, are central events in cancer pathogenesis1–3. 
Analysis of focal SCNAs has led to the identification of many critical cancer driver 
genes4–8. However, for focal amplifications and deletions that occur outside of coding 
regions, the identity of specific targets has remained unclear. Non-coding regions harbor cis-
regulatory elements, termed enhancers, that are bound by transcription factors and establish 
lineage-specific expression programs that define cellular identity9–13. Enhancers are 
characterized by the histone modifications H3K4me1 and H3K27ac, binding of coactivators 
such as p300, and increased chromatin accessibility as defined by DNaseI 
hypersensitivity14–19. Methods such as chromatin immunoprecipitation sequencing (ChIP-
seq) and DNaseI hypersensitivity sequencing (DNaseI-seq) have revealed the presence of 
large clusters of enhancers, termed super-enhancers due to the high level of transcription 
factor binding associated with these regions19–25. Previously, super-enhancers have been 
implicated in oncogene activation in cancer through focused analyses of individual tumor 
types22,26–30. In this study, we systematically investigate SCNAs of non-coding regions at a 
pan-cancer scale and provide evidence suggesting that focal amplifications of super-
enhancers are a common mechanism for upregulating the expression of cancer driver genes.
Statistical methods such as GISTIC (Genomic Identification of Significant Targets in 
Cancer)2,31 have been developed to identify genomic regions that are recurrently amplified 
or deleted across cancer types. We examined GISTIC analysis of The Cancer Genome Atlas 
(TCGA) copy number results for 10,534 samples across 29 tumor types, and identified non-
coding focal amplification peaks in 19 of these tumor types after filtering out amplicons 
containing genes in the Reference Sequence (Refseq) database (Fig. 1a and Supplementary 
Table 1). For 12 out of the 19 tumor types, H3K27ac ChIP-seq data from corresponding 
tissue or cell lines were available from either public datasets such as ENCODE and the 
Roadmap Epigenomics project20–22,32 or from our own collection (Supplementary Table 2). 
From the 55 focally amplified non-coding regions identified by our analysis, we found six 
tissue-specific focal amplification peaks harboring super-enhancers as defined by previous 
criteria22,25,33 (Fig. 1b).
The six focally amplified super-enhancers reside in four distinct genomic loci. The focal 
amplification on chr13q identified in head and neck squamous cell carcinoma (HNSC) 
(~110 kb, chr13:73880690-73990596) and esophageal carcinoma (ESCA) (~162 kb, 
chr13:73880413-74042621), is located between the Kruppel-like transcription factors, KLF5 
and KLF12 (Fig. 1c). ChIP-seq profiling of H3K27ac in the HNSC cell line BICR-31 
revealed that the focal amplification harbors a cluster of three super-enhancers, which we 
termed KLF5-HNSE (KLF5 Head and Neck squamous cell carcinoma Super-Enhancers). 
The expression of KLF5, but not KLF12, is significantly higher in HNSC tumors with 
KLF5-HNSE amplification, suggesting that KLF5 is the target gene (Fig. 1c, Supplementary 
Fig. 1). In total, ~3% (n = 15) of HNSC cases have amplification of KLF5-HNSE in the 
absence of KLF5 gene amplification (Fig. 1c). Similarly, the ESCA amplicon also harbors a 
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super-enhancer based on the H3K27ac ChIP-seq profile of esophageal cells and ESCA 
tumors with this amplicon exhibited a trend towards increased KLF5 expression 
(Supplementary Fig. 2). In lung adenocarcinomas and lung squamous cell carcinomas, 
KLF5 is also significantly mutated with recurrent missense alterations (Campbell et. al., in 
preparation). These results suggest that KLF5 is a putative oncogene which can be 
upregulated in tumors by super-enhancer amplification.
Additional focal amplification peaks on chr13q in colorectal carcinoma (CRC) (~21 kb, 
chr13:27523026-27544353) and chr20q in liver hepatocellular carcinoma (LIHC) (~22kb 
chr20:48997377-49019434) were identified. ChIP-seq profiling of H3K27ac in colon crypt 
cells32 and in the hepatocellular carcinoma cell line HepG220 revealed that these amplicons 
contain super-enhancers (Fig. 1d,e). CRC tumors containing the chr13q amplicon exhibited 
significantly higher expression of the nearest gene, ubiquitin specific peptidase 12, USP12, a 
deubiquitinating enzyme implicated in prostate cancer34 (Fig. 1d and Supplementary Fig. 1). 
In LIHC tumors with the chr20q amplicon, the expression of the second nearest gene 
PARD6B, rather than the closest gene PTPN1, is upregulated, suggesting that PARD6B is 
the target gene (Fig. 1e and Supplementary Fig. 1). PARD6B is part of an intracellular 
signaling complex involved in cellular polarity; its over-expression may lead to 
dysregulation of cell orientation and cellular transformation35.
Frequent non-coding amplifications were identified near the MYC gene, with two distinct 
focal amplification peaks situated ~450 and ~800 kb 3′ to the MYC oncogene in lung 
adenocarcinoma (LUAD) and uterine corpus endometrial carcinoma (UCEC), respectively 
(Fig. 2a). These peaks are distinct from focally amplified super-enhancer regions ~1.5 Mb 
and ~1.7 Mb 3′ to MYC previously identified in T-cell acute lymphoblastic leukemia (T-
ALL) and acute myeloid leukemia (AML), respectively26,30. The lung adenocarcinoma peak 
(chr8:129166547-129190290) encompasses a 23 kb non-coding region that is part of a 
super-enhancer as defined by the H3K27ac ChIP-seq profile from A549 lung 
adenocarcinoma cells, which we refer to as MYC-LASE (MYC Lung Adenocarcinoma 
Super-Enhancer). In total, ~17% of lung adenocarcinoma cases (n = 86) have a focal 
amplification of MYC-LASE that is co-amplified with MYC, while ~2% (n = 11) of cases 
have a focal amplification of MYC-LASE without concurrent amplification of MYC (Fig. 
2a). Four out of 52 (~8%) lung adenocarcinoma cell lines profiled for copy-number 
alterations by the Cancer Cell Line Encyclopedia (CCLE) project36 also have focal 
amplification of MYC-LASE in the absence of MYC amplification (Supplementary Fig. 3). 
Rearrangement analysis of whole genome sequencing data from 70 lung adenocarcinoma 
tumor/normal pairs6,37 revealed two tumors with somatic focal amplification of MYC-LASE 
occurring as a tandem duplication event (Fig. 2b). We performed H3K27ac ChIP-seq in two 
additional lung adenocarcinoma cell lines, NCI-H2009 and NCI-H358, the lung squamous 
cell carcinoma (LUSC) line HCC95 and the small cell lung carcinoma (SCLC) cell line 
NCI-H2171 and validated that MYC-LASE is part of a lung adenocarcinoma-specific super-
enhancer (Fig. 2c and Supplementary Fig. 3).
The endometrial carcinoma peak (chr8:129543949-129554294) encompasses a 10 kb non-
coding region that harbors a super-enhancer as defined by the H3K27ac ChIP-seq profile of 
the endometrial carcinoma cell line Ishikawa (Fig. 2d), and which we refer to as MYC-
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ECSE (MYC Endometrial carcinoma Super-Enhancer). Approximately 10% of cases (n = 
54) have focal amplification of both MYC-ECSE and MYC, while ~4% (n = 20) of cases 
have focal amplification of only MYC-ECSE (Fig. 2a). The H3K27ac and p300 ChIP-seq 
profiles of MYC-LASE and MYC-ECSE indicate that each super-enhancer is active only in 
cell lines from each respective tumor type (Fig. 2c–d and Supplementary Fig. 4).
Distal enhancers regulate target gene expression through chromatin loops that connect 
enhancers with target gene promoters38–40. We performed chromosome conformation 
capture (3C) assays in A549 and Ishikawa cells and found that MYC-LASE physically 
interacts with the MYC promoter only in A549 cells, and reciprocally, that MYC-ECSE 
physically interacts with the MYC promoter only in Ishikawa cells (Fig. 2e). In addition, 
tumors with amplification of MYC alone or MYC-LASE/ECSE alone have higher MYC 
expression than tumors lacking either amplification (Fig. 2f). These results suggest that both 
MYC-LASE and MYC-ECSE drive MYC expression through lineage-specific chromatin 
loops.
To determine if copy number gain of super-enhancers drives oncogene expression and 
tumorigenesis, we focused on MYC-LASE. The binding profile for p300, a marker for 
enhancer activity14, revealed five constituent enhancers (e1–e5) within MYC-LASE in A549 
and NCI-H2009 cells, which overlap with H3K27ac enrichment and DNase I 
hypersensitivity (Fig. 3a). Among the five constituent enhancers, the e3 enhancer is 
associated with the highest p300 binding as well as the greatest DNase I hypersensitivity 
(Fig. 3a). In luciferase reporter assays in A549, NCI-H358 and NCI-H2009 cells, the e3 
enhancer was also found to have the strongest activity (Fig. 3b). In contrast, MYC-LASE 
has no detectable enhancer activity in HEK293 cells, confirming that this super-enhancer is 
specific to lung adenocarcinoma (Supplementary Fig 5). Duplication of the e3 enhancer in 
the luciferase reporter construct resulted in >2-fold higher luciferase expression relative to a 
single copy of e3, demonstrating that an increase in copy number of the enhancer region 
may upregulate target gene expression (Fig. 3c).
We next aimed to identify the transcription factors that are required for lung 
adenocarcinoma-specific activity of the e3 enhancer. We tested ~350 bp fragments of the 
~1.5kb e3 region in luciferase reporter assays and discovered that a minimal ~148bp region 
(mini-e3) was responsible for the preponderance of e3 enhancer activity (Fig. 4a). 
Transcription factor motif analysis using the ENCODE motif dataset41 identified GATA3, 
FOXA1, NFE2L2 and CEBPB as candidate factors capable of binding to mini-e3 (Fig. 4b). 
Deletion of specific transcription factor binding motif sequences within mini-e3 
demonstrated that the NFE2L2 and CEBPB motifs were necessary to maintain maximal e3 
enhancer activity (Fig. 4c). Short interfering RNA (siRNA)-mediated knockdown of 
NFE2L2 and CEBPB in A549 cells led to a significant reduction in e3-driven luciferase 
reporter activity as compared to control siRNAs (Fig. 4d and Supplementary Fig. 6). The 
binding of NFE2L2 and CEBPB to the super-enhancer was subsequently confirmed by 
ChIP-seq, with greatest enrichment at the e3 constituent enhancer (Fig. 4e).
To investigate the functional role of the amplified e3 enhancer region, we first targeted 
catalytically inactive Cas9 (dCas9) fused to the Kruppel-associated box (KRAB) 
Zhang et al. Page 4
Nat Genet. Author manuscript; available in PMC 2016 June 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
transcriptional repressor domain42,43 to inhibit e3 enhancer activity in NCI-H2009 lung 
adenocarcinoma cells that contain four copies of MYC-LASE. Targeting KRAB-dCas9 to 
the e3 enhancer using two independent single guide RNAs (sgRNAs) resulted in a marked 
decrease in H3K27ac, compared to cells expressing a control non-targeting sgRNA or 
KRAB-dCas9 only (Fig. 5a). A significant reduction (~50%) of MYC gene expression was 
also observed after KRAB-dCas9 mediated repression, confirming MYC as a target gene of 
the e3 enhancer (Fig. 5b and Supplementary Fig. 7). Furthermore, comparison of RNA 
sequencing (RNA-seq) data with gene expression signatures44–47 for MYC using Gene Set 
Enrichment Analysis (GSEA)48 revealed that e3 enhancer repression is associated with a 
significant decrease in the expression of MYC target genes (Fig. 5c). Finally, repression of 
the e3 enhancer led to a significant decrease in both anchorage-independent and clonogenic 
growth (Fig. 5d and 5e; Supplementary Fig. 8), demonstrating that activity of the e3 
enhancer is critical for the tumorigenicity of lung adenocarcinoma cells.
We also used the CRISPR/Cas9 system to specifically delete the e3 enhancer in NCI-H2009 
cells. Two independent pairs of sgRNAs were used to target Cas9 to the boundaries of the e3 
enhancer. Deletion of e3 was detected by PCR in cells transduced with either pair of e3-
targeting sgRNAs, but not in cells transduced with a pair of non-targeting sgRNAs (Fig. 6a–
c). Deletion of the e3 enhancer region resulted in a ~30% reduction in MYC expression (Fig. 
6d) and a significant impairment of both anchorage-independent and clonogenic growth 
(Fig. 6e and 6f; Supplementary Fig. 9). These results suggest that copy number gain of the 
e3 enhancer region drives MYC over-expression, which contributes to the tumorigenic 
phenotype.
MYC overexpression has been observed as a consequence of rearrangements with the IgH 
locus in Burkitts lymphoma22,49 (Fig. 6g, lower left diagram) as well as through 
amplifications of the MYC gene itself in several tumor types2 (Fig. 6g, lower left middle 
diagram). Similar to our findings, focal amplification of different super-enhancer regions 
downstream of MYC have been reported in T-ALL and AML26,30. Collectively, these data 
suggest that copy number gain of super-enhancers is highly lineage-specific but may be a 
common mechanism for upregulating MYC expression in diverse types of cancer (Fig. 6g, 
lower right panel).
Chromosomal rearrangements that result in the placement of a super-enhancer adjacent to an 
oncogene have been described in multiple myeloma, leukemia, medulloblastoma and 
glioblastoma22,27,29,50. Here, we systematically investigate another somatic structural 
alteration – focal copy number amplification – through pan-cancer analysis of 10,534 tumors 
integrating genomic, epigenomic and transcriptomic data. We report six super-enhancer 
regions to be focally amplified across different cancer types. These super-enhancer 
amplifications are associated with over-expression of the MYC oncogene as well as the 
KLF5, USP12 and PARD6B genes. Thus, focal amplification of super-enhancers represents 
a new class of structural alterations with functional implications in cancer. Further 
identification and characterization of these events through whole-genome and long-read 
sequencing approaches may shed insight into mechanisms of tumorigenesis and provide 
novel targets for therapeutic intervention.
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Online methods
Pan-Cancer copy number alteration analysis
GISTIC analyses were performed in 29 tumor types (Supplementary Table 1), using copy 
number data from version 3.0 of the SNP pipeline on 22-Oct-2014 from TCGA copy 
number portal2,31. Focal amplification peaks of non-coding regions were found in 19 tumor 
types of which 12 tumor types had H3K27ac ChIP-seq data available for the relevant tissue 
type (Supplementary Table 1 and 2).
Cell lines
BICR-31 was obtained from Sigma-Aldrich, and A549, NCI-H2009, NCI-H358, HCC95, 
and Ishikawa cells were obtained from the American Type Culture Collection. Cells were 
cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin-
streptomycin.
ChIP-seq
Chromatin-immunoprecipitation followed by massive parallel sequencing (ChIP-seq) was 
performed as previously described51,52. Briefly, cells were first crosslinked and lysed. The 
chromatin extract was sonicated using a Diagenode bioruptor and immunoprecipitated with 
an anti-H3K27ac antibody (Abcam, ab4729). DNA was extracted and processed with the 
NEB ChIP-seq library prep kit (E6200S) and sequenced on an Illumina MiSeq (50bp single-
end). Sequence reads were aligned to hg19 genome by BWA53 and H3K27ac binding sites 
were called by MACS54. ChIP-seq was done in duplicate and the results were uploaded to 
the Gene Expression Omnibus (GSE66992). ChIP-seq data from public datasets are listed in 
Supplementary Table 2.
RNA-seq
RNA was extracted using the Qiagen RNeasy kit with on-column DNase I treatment. 1 ug of 
RNA for each sample was processed with the NEBNext PolyA mRNA Magnetic Isolation 
Module (NEB #E7490) and further processed with the NEBNext Ultra Directional RNA 
Library Prep Kit (NEB #E7420S). RNA libraries were then sequenced on an Illumina MiSeq 
(75bp paired-end). Sequence reads were aligned using the PRADA pipeline and differential 
gene expression was called using the Cufflinks pipeline. RNA-seq was done in duplicate and 
the results were uploaded to the Gene Expression Omnibus (GSE72001).
Super enhancer identification
Super enhancers were called from the ROSE pipeline24,55 using H3K27ac ChIP-seq data 
including aligned reads and binding sites called from MACS. Briefly, enhancers were first 
clustered based on their distance to each other, and then super-enhancers were identified 
based on the enrichment of the H3K27ac ChIP-seq signal of each enhancer cluster.
Luciferase reporter assays
The pGL3 promoter luciferase reporter system (Promega) was used. The enhancer regions 
were cloned upstream of the pGL3 minimal promoter region using MluI and XhoI restriction 
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enzyme sites. The enhancer luciferase constructs were then co-transfected with a control 
Renilla luciferase construct into cells using Fugene 6 (Promega). The luciferase signal was 
first normalized to the Renilla luciferase signal and then normalized to the signal from the 
empty pGL3 plasmid. Primers used for cloning are listed in Supplementary Table 3.
3C-qPCR
Chromosome conformation capture (3C) assays were performed as previously 
described52,56. 3C ligation products were quantified by SYBR-green based PCR. BAC 
libraries (RP11-628C14, RP11-55J15, CTD-2034C18, RP11-69H6 and CTD-2218N24) 
containing DNA fragments covering the tested regions were used as template controls for 
normalizing digestion, ligation and primer efficiency. 3C primers and genomic coordinates 
of their targets are listed in Supplementary Table 3.
Site-directed deletion of motif sequence
The QuikChange Lightning site-directed mutagenesis system (Agilent Technologies Inc.) 
was used to generate deletions of the predicted motif sequences in the e3 region. Primers 
used are listed in Supplementary Table 3.
CRISPR/Cas9 mediated repression and deletion of the enhancer region
CRISPR/Cas9 single-guide RNAs (sgRNA) were identified using the MIT CRISPR Design 
tool and control non-targeting sgRNAs were selected from the GeCKOv2 library57. All 
sgRNA sequences are listed in Supplementary Table 3. For repression of the e3 enhancer, 
the KRAB-dCas9 fusion gene was PCR amplified from pHR-SFFV-KRAB-dCas9-P2A-
mCherry (Addgene #60954) and cloned into the XbaI/BamHI sites of lentiCas9-blast 
(Addgene #52962) to generate lenti-KRAB-dCas9-blast. SgRNAs were cloned into 
lentiGuide-Puro (Addgene #52963). NCI-H2009 cells were first infected with lenti-KRAB-
dCas9-blast and selected with 6μg/ml of blasticidin. Cells stably expressing KRAB-dCas9 
were then subsequently infected with sgRNAs and selected with 2μg/ml puromycin. For 
deletion of the e3 enhancer, tandem U6-promoter-sgRNA and H1-promoter-sgRNA cassettes 
were cloned into lentiCRISPR_v2 (Addgene #60954) for single vector expression of two 
sgRNAs as follows: 1) U6-sgRNA and H1-sgRNA products were generated by PCR 
amplification using the primers listed in Supplementary Table 3, 2) PCR products were then 
digested with BsmBI to generate compatible sticky ends, 3) finally, three-way ligation of the 
two PCR products and BsmBI-digested lentiCRISPR_v2 was performed using T7 DNA 
ligase (NEB #M0318). Control ‘empty’ lentiCRISPR_v2 lacking expression of any sgRNAs 
was generated by BsmBI digestion, followed by blunting of ends (NEB #E1201) and 
ligation with T4 DNA ligase (NEB #M0202). After infection, cells were selected with 
2μg/ml of puromycin. To detect deletion of the e3 enhancer, genomic DNA was first 
extracted using QuickExtract DNA extraction solution (Epicentre #QE09050) and then used 
for PCR using Q5 high-fidelity DNA polymerase (NEB #M0491) with the primers listed in 
Supplementary Table 3.
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Anchorage-independent and clonogenic growth assays
To measure anchorage-independent growth, a base layer of 2ml of 0.75% select agar in 
RPMI/10% FBS was first prepared in each well of a 6-well plate. Cells were then plated in 
1ml of a top layer of 0.3% select agar in RPMI/10% FBS. After 2 weeks, wells were 
photographed and colonies were counted using CellProfiler software. For the clonogenic 
growth assay, approximately 300 cells were seeded in 2ml of RPMI/10% FBS in each well 
of a 6-well plate. Media was completely refreshed every 7 days. Cells were fixed with 100% 
methanol and then stained with 0.5% crystal violet in 25% methanol. Wells were destained 
using 10% acetic acid and the crystal-violet signal was read at 595 nm on a Spectramax 
spectrophotometer.
TaqMan gene expression assay
Quantitative PCR was performed in duplicate using the TaqMan Universal PCR Mastermix 
on an ABI Quantstudio 6 instrument. The following premade 5′ nuclease assays were 
ordered from Integrated DNA Technologies: MYC (Hs.PT.58.26770695), NCL (Hs.PT.
58.1260587), CDK4 (Hs.PT.58.584267), ODC1 (Hs.PT.58.27029915), NPM1 (Hs.PT.
58.40019160) and internal reference HPRT1 (Hs.PT.58v.45621572). Relative expression 
levels were calculated using the ΔΔCt method.
siRNA-directed gene silencing
A549 cells were transfected with scrambled siRNA (siNC), siNFE2L2 or siCEBPB using 
Lipofectamine RNAiMAX (Life Technologies). RNA was extracted 48 hours after 
transfection using the Qiagen RNeasy Kit with on-column DNase treatment. Pre-verified 
Silencer Select siRNAs (Life Technologies, s9491 and s9492 for NFE2L2, and s2891 and 
s2892 for CEBPB) were used. To assess the effect of siRNAs, western-blot was performed 
using antibodies against NFE2L2 (Abcam ab62352), CEBPB (Santa Cruz sc-150) and β-
ACTIN (Cell signaling #3700).
Public data usage
Accession numbers for ENCODE data, the Roadmap project data and other public datasets 
used in this study are listed in Supplementary Table 2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Pan-cancer analysis identifying focally amplified super-enhancers
(a) Schematic flow chart of pan-cancer GISTIC analysis of 10,534 tumors from 29 tumor 
types identifying non-coding focal amplifications of super-enhancers. (b) List of non-coding 
focal amplification regions harboring super-enhancers. UCEC: uterine corpus endometrial 
carcinoma, HNSC: head and neck squamous cell carcinoma, LUAD: lung adenocarcinoma, 
CRC: colorectal carcinoma, LIHC: liver hepatocellular carcinoma, CESC: cervical 
squamous cell carcinoma, ESCA: esophageal carcinoma. (c) The focal amplification on 
chr13q identified in HNSC. ChIP-seq profile of H3K27ac and super-enhancer regions from 
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the HNSC cell line BICR-31. Log2 transformed expression level (RPKM) of KLF5 in 
HNSC tumors with focal amplification of KLF5-HNSE alone (n = 14) and tumors without 
the amplification (n = 288). Box plot: Middle bar, median; lower and upper box limits, 25th 
and 75th percentiles, respectively; whiskers, min and max. The P-value is derived from a t-
test; (**) p≤0.01; (***) p≤0.001. (d) The focal amplification region on chr13q identified in 
CRC. ChIP-seq profile of H3K27ac and super-enhancer regions from colon crypt32. Log2 
transformed expression level (RPKM) of USP12 in CRC tumors with focal amplification of 
USP12-CCSE alone (n = 6) and tumors without the amplification (n = 127). (e) The focal 
amplification on chr20q identified in LIHC. ChIP-seq profile of H3K27ac and super-
enhancer regions from the LIHC cell line HepG2. Log2 transformed expression level 
(RPKM) of PARD6B in LIHC tumors with focal amplification of PARD6B-LCSE alone (n 
= 7) and tumors without the amplification (n = 245).
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Fig. 2. Lineage-specific focal amplification of super-enhancers adjacent to the MYC gene
(a) Focal amplification peaks adjacent to MYC identified by GISTIC in lung 
adenocarcinoma (n = 11/515) and UCEC (n = 20/539). (b) Whole genome sequencing 
rearrangement analysis of two lung adenocarcinomas reveals tandem duplications, indicated 
by the curves. H3K27ac ChIP-seq profile and super-enhancer regions of the LUAD cell lines 
A549, NCI-H2009 and NCI-H358 (c) and the UCEC cell line Ishikawa (d) in the MYC 
region. (e) 3C interaction frequency ± SEM measured by chromosome conformation capture 
assays (n = 3) in A549 and Ishikawa cells. The 3C ‘anchor’ primer targets the MYC 
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promoter region, while the 3C ‘bait’ primers target the non-coding regions 3′ to MYC. The 
P-value is derived from a t-test; (**) p≤0.01; (***) p≤0.001. (f) Left: Log2 transformed 
expression level (RPKM) of MYC in LUAD tumors with focal amplification of either MYC 
alone (n = 7) or MYC-LASE alone (n = 11) and tumors without these amplifications (n = 
235). Right: UCEC tumors with focal amplification of either MYC alone (n = 10) or MYC-
ECSE (n = 14) and tumors without these amplifications (n = 250). Box plot: Middle bar, 
median; lower and upper box limits, 25th and 75th percentiles, respectively; whiskers, min 
and max. The P-value is derived from a t-test; (***) p≤0.001.
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Fig. 3. The activity of the MYC-LASE is predominantly driven by the e3 constituent enhancer
(a) H3K27ac, p300 binding and DNase I hypersensitivity profiles in A549, NCI-H2009 and 
NCI-H358 cells reveal the constituent enhancers e1-e5 within the super-enhancer region. (b) 
Luciferase reporter assay (n = 3) measuring enhancer activity of e1-e5 in A549, NCI-H358 
and NCI-H2009 lung adenocarcinoma cells. The pGL3 plasmid without the enhancer region 
(Empty) is used as a negative control. (Y-axis) Relative Luciferase units are normalized to 
Renilla signal ± SEM. The P-value is derived from a t-test; (**) p≤ p0.01; (***) p≤0.001. (c) 
Enhancer activity of a duplicated e3 enhancer (2×e3) ± SEM as measured by luciferase 
reporter assay (n = 3). The P-value is derived from a t-test; (***) p≤0.001.
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Fig. 4. Identification of transcription factors required for the activity of the e3 enhancer
(a) Enhancer activity ± SEM of small fragments (a-f) of the e3 enhancer as assessed by 
luciferase reporter assays (n = 3) in A549 LUAD cells. The fragments c and d show 
comparable enhancer activity relative to the intact e3 enhancer, while other fragments show 
minimal enhancer activity. The P-value is derived from a t-test; (***) p≤0.001. (b) 
Transcription factor DNA recognition motifs are identified in the mini-e3 enhancer region 
that is defined by the c and d fragments overlap. (c) The luciferase reporter expression level 
± SEM after deletion of individual transcription factor motif sequence in the e3 regions. The 
P-value is derived from a t-test (n = 3); (**) p≤0.01; (***) p≤0.001. (d) Luciferase reporter 
expression level ± SEM after silencing NFE2L2 or CEBPB by siRNA (n = 3). The P-value 
is derived from a t-test; (*) p≤0.05; (**) p≤0.01. (e) ChIP-seq profile of NFE2L2 and 
CEBPB in the e1–e5 enhancer regions in A549 cells.
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Fig. 5. KRAB-dCas9 mediated repression of the e3 enhancer reveals MYC as a direct target
(a) Upper: the design of KRAB-dCas9 mediated repression of the e3 enhancer. Bottom: 
ChIP-seq of H3K27ac in NCI-H2009 cells with and without KRAB-dCas9 enhancer 
repression. p300 ChIP-seq profile in parental NCI-H2009 cells indicates the e3 enhancer 
region. sg-Empty: no sgRNA; sg-Control: sgRNA that is predicted to not recognize any 
genomic regions; sg-e3KRAB #1 and sg-e3KRAB #2: two separate sgRNAs recognizing the 
e3 enhancer region. (b) The expression level of MYC ± SEM as measured by quantitative 
PCR in NCI-H2009 cells with and without KRAB-dCas9 mediated repression of the e3 
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enhancer (n = 2). (c) GSEA analysis of RNA-seq data generated in NIC-H2009 cells with 
and without KRAB-dCas9 mediated e3 enhancer repression reveals that genes regulated by 
e3 repression are enriched in MYC target genes identified by previous studies44–47. The 
cellular transformation efficiency ± SEM as measured by anchorage-independent growth (n 
= 3) (d) and the cellular proliferation rate ± SEM as measured by clonogenic assays (n = 3) 
(e) in NCI-H2009 cells with and without KRAB-dCas9 mediated repression of the e3 
enhancer. The P-value is derived from a t-test; (*) p≤0.05; (**) p≤0.01; (***) p≤0.001.
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Fig. 6. CRISPR/Cas9 mediated deletion of the e3 enhancer impairs the oncogenic effect of the e3 
enhancer amplification
(a) Upper: design of CRISPR/Cas9 mediated deletion of the e3 enhancer. Primers used to 
validate the e3 enhancer deletion are indicated. Bottom: Gel pictures of PCR amplification 
of genomic DNA using primers outside and inside the e3 enhancer region. sg-Empty: no 
sgRNA; sg-Control: a pair of sgRNAs that are predicted to not recognize any genomic 
regions; sg-e3del #1 and sg-e3del #2: two separate pairs of sgRNAs recognizing boundaries 
of the e3 enhancer region. PCR products were cloned into individual vectors and sequenced. 
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Sequencing results represent the deletions induced by sg-e3del #1 (b) and sg-e3del #2 (c). 
The expression level of MYC ± SEM as measured by quantitative PCR (n = 2) (d), the 
cellular transformation efficiency ± SEM as measured by anchorage-independent growth (n 
= 3) (e) and the cellular proliferation rate ± SEM as measured by clonogenic assays (n = 3) 
(f) in NCI-H2009 cells with and without CRISPR/Cas9 mediated deletion of the e3 
enhancer. The P-value is derived from a t-test; (*) p≤0.05; (**) p≤0.01. (g) Schematic 
representation of genomic structural variants activating MYC expression in cancer.
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